The changes you're referring to are proposed amendments to the patented medicines regulations, which would modernize the way the Patented Medicine Prices Review Board looks at setting non-excessive prices for patented medicine. They were published in the Canada Gazette last December. The consultation period on that closed in February. The department continues to evaluate the results of that consultation and continues dialogue with all the stakeholders before proceeding to Canada Gazette, Part II.
We don't have a definitive date for publication of the final regulations. We're certainly well aware of the comments and concerns of the stakeholder community. We can assure you that both the department and our colleagues at the board continue to work with those stakeholder groups, because we collectively understand the importance as a regulator of certainty, predictability and transparency in the application of those regulations to their ultimate success for Canadians overall and ensuring that Canadians continue to have access not only to the types of drugs that we're talking about today, but all patented medicines.
Thank you.